Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Consultation

Draft guidance for recurrent ovarian cancer

The National Institute for Health and Care Excellence (NICE) has published draft guidance that covers five drugs — paclitaxel, pegylated liposomal doxorubicin hydrochloride (PLDH), topotecan, trabectedin and gemcitabine — for treating recurrent ovarian cancer. The guidance recommends paclitaxel and PLDH for treating recurrent ovarian cancer but proposes not recommending gemcitabine, topotecan and trabectedin for treating the first recurrence of platinum-sensitive ovarian cancer (where the disease responds to first-line, platinum-based therapy but returns over six months after this treatment). The guidance is available for consultation from the NICE website until 15 December 2015.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200186

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.